This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Global Neurostimulation Industry

Overview III-1

Neurostimulation Products Market to Witness Growth III-1

Product Segments Ranked by Growth III-2

Table 28: Neurostimulation Market in the US (2010-2018):

Product Segments Ranked by Growth (Sales in US$

million)(includes corresponding Graph/Chart) III-2

Table 29: Neurostimulation Market in the US (2010-2018):Product Segments Ranked by Growth (Sales in Units)(includes corresponding Graph/Chart) III-3

Table 30: Neurostimulation Market in the US (2011): Unit

Sales & Percentage Breakdown by Product Segment - Spinal

Cord Stimulators (SCS), Deep Brain Stimulators (DBS),

Sacral Nerve Stimulators (SNS), Vagus Nerve Stimulators

(VNS) and Gastric Electric Stimulators (GES) (includes

corresponding Graph/Chart) III-3

Table 31: Neurostimulation Market in the US (2011): ValueSales (in US$ Million) & Percentage Market Share byProduct Segment - Spinal Cord Stimulators (SCS), DeepBrain Stimulators (DBS), Sacral Nerve Stimulators (SNS),Vagus Nerve Stimulators (VNS) and Gastric ElectricStimulators (GES) (includes corresponding Graph/Chart) III-4Potential Growth for Neurostimulation Systems in the US III-4Spinal Cord Stimulation Products Market III-5Table 32: US Spinal Cord Stimulator Market (2011):Percentage Share Breakdown by Company - Medtronic,St.Jude Medical Boston Scientific (includes correspondingGraph/Chart) III-5Sacral Nerve Stimulation Products Market III-5Deep Brain Stimulation Products Market III-6Shift Away from Orthopaedic and Cardiovascular Device Markets III-6Trends in the Embolotherapy Market III-7Neurovascular Stents Market Attracting Cardiovascular Companies III-8Migraine Devices - New Frontiers for Neurostimulation III-8Competitive Landscape III-8Table 33: Leading Players in the US NeurostimulationMarket (2011): Percentage Breakdown of Revenues forMedtronic, Advanced Bionics, St. Jude Medical, Cyberonicsand Others (includes corresponding Graph/Chart) III-9Neurostimulation Device Approvals III-9Recent Industry Activity III-13Product Innovations/ Introductions III-17Key Players III-19B.Market Analytics III-22Table 34: US Recent Past, Current & Future Analysis forNeurostimulators by Product Segment - Spinal CordStimulators (SCS), Deep Brain Stimulators (DBS), SacralNerve Stimulators (SNS), Vagus Nerve Stimulators (VNS), andGastric Electric Stimulators (GES) Markets IndependentlyAnalyzed with Annual Sales Figures in Units for Years 2010through 2018 (includes corresponding Graph/Chart) III-22

Table 35: US Recent Past, Current & Future Analysis for

Neurostimulators by Product Segment - Spinal Cord

8 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.74 -0.54%
FB $119.18 1.20%
GOOG $709.74 1.20%
TSLA $214.93 1.60%
YHOO $37.25 0.84%


Chart of I:DJI
DOW 17,727.66 +66.95 0.38%
S&P 500 2,057.46 +6.83 0.33%
NASDAQ 4,733.1610 +16.0670 0.34%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs